Business News • PR NewsWire • NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients

NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients

NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients

SAN ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Can

View More : http://www.prnewswire.com/news-releases/nktr-102-demonstrates-significant-efficacy-as-single-agent-in-second--or-third-l...

Releted News by prnewswire

Cellcom Israel Ltd. Announces Marketing VP Resignation From Office

European Card Acquiring Forum, B2B Platform for Card Acquiring Information Exchange, Announces the 'Guiding Hand' Awards

Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine

Rentrak Announces Official Box Office Totals for Weekend of December 10, 2010

U.S. Online Holiday Spending Approaches $22 Billion for the Season, Up 12 Percent vs. Year Ago